Bajaj Electricals launches new Switchgear range under Lighting Solutions segment
Bajaj Electricals Limited has announced the launch of its new 'Switchgear' range under the company's Lighting Solutions segment. The product was officially launched on August 7, 2025, and caters to the domestic market.
Named BAJAJ SECURA™, the new switchgear line includes Miniature Circuit Breakers (MCBs), Residual Current Circuit Breakers (RCCBs), Isolators, Changeover Switches, and Distribution Boards (DBs). These are engineered to offer high levels of safety, performance, and ease of installation, targeting both residential and commercial users.
Rajesh Naik, COO – Lighting Solutions at Bajaj Electricals, stated that this strategic expansion builds on Bajaj's trusted legacy and brings dependable protection to Indian homes. The products are specifically designed to serve electricians and project contractors across Tier 2 and Tier 3 markets, where safety and reliability are top priorities.
With shock-proof terminals, fast-tripping mechanisms, and silver-copper contacts for consistent performance, each unit is quality-tested to meet industry standards.
The move marks Bajaj Electricals' entry into the protective electrical component space and aligns with its goal to offer end-to-end lighting and safety solutions.
Ahmedabad Plane Crash
Aditya Bhagchandani serves as the Senior Editor and Writer at Business Upturn, where he leads coverage across the Business, Finance, Corporate, and Stock Market segments. With a keen eye for detail and a commitment to journalistic integrity, he not only contributes insightful articles but also oversees editorial direction for the reporting team.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Wire
13 minutes ago
- Business Wire
Cohesys Announces First-in-Human Use of Investigational BoneTape™ in Craniofacial Fracture Repair
TORONTO--(BUSINESS WIRE)--Cohesys Inc., a Toronto-based medical device developer of resorbable fixation technologies, today announced that the first participants have undergone treatment with BoneTape™, an investigational device designed for the fixation of non-load-bearing craniofacial fractures. The procedures were completed as planned and mark the first clinical use of this drill- and screw-free fixation system. "Reaching this milestone is significant for Cohesys as we evaluate BoneTape's potential to offer a simpler, patient-friendly approach to fracture repair,' said Dr. Michael Floros, CEO of Cohesys. 'The data from this study will inform our regulatory strategy and commercialization pathway.' 'This marks an exciting step forward for the study, and it's a privilege to be part of an effort exploring new techniques in facial-fracture treatment,' said Dr. Jeffrey A. Fialkov, MD, MSc, FRCSC, Head of the Division of Plastic and Reconstructive Surgery at Sunnybrook Health Sciences Centre, Associate Professor in the Department of Surgery at the University of Toronto, and Principal Investigator for the study. 'BoneTape's hardware-free approach is intended to simplify surgery and may improve the recovery experience for patients.' Device- and procedure-related risks—including infection, non-union, and re-operation—will be actively monitored throughout the study's follow-up period. Dr. Janaina Bortolatto, VP, Clinical Operations for Cohesys noted, 'The completion of these first cases with BoneTape reflects the dedication of our team and our clinical partners. We are focused on gathering the clinical data needed to evaluate BoneTape for potential future use.' BoneTape is applied with a handheld applicator that affixes the resorbable fixation device to bone surfaces without drilling or screws. The study will determine whether this design performs as intended, potentially sparing patients from device-related complications and the need for hardware-removal procedures. About Cohesys Cohesys Inc. develops advanced resorbable fixation solutions aimed at simplifying surgery and improving bone healing. BoneTape, the company's primary technology, is currently under clinical investigation. For more information, visit BoneTape™ is a trademark of Cohesys Inc. Regulatory Status BoneTape is an investigational device; it is not licensed for commercial sale. Its use in this clinical study has been authorized by Health Canada under an Investigational Testing Authorization (ITA). Safety and effectiveness have not been established. Identifier: NCT06600854
Business Wire
an hour ago
- Business Wire
ConcertAI Appoints Michael Myshrall as Chief Financial Officer
CAMBRIDGE, Mass.--(BUSINESS WIRE)-- ConcertAI, a leader in oncology generative and agentic AI SaaS and multi-modal data (MMD) solutions for healthcare and life sciences, today announced the appointment of Michael Myshrall as chief financial officer (CFO). Myshrall brings over two decades of financial leadership experience in SaaS, artificial intelligence (AI) and technology sectors, positioning him to help accelerate ConcertAI's continued expansion and innovation in AI-powered clinical research and care. Myshrall joins ConcertAI following a distinguished career leading financial operations for high-growth technology companies. Most recently, he served as CFO at Afiniti, a leader in customer experience AI software, where he led an international finance organization and helped navigate a complex financial recapitalization of the business. Previously, Myshrall served as CFO for NASDAQ-listed cybersecurity company Cyren, where he raised over $100 million in equity and debt capital, including a majority sale to private equity firm Warburg Pincus. He was also CFO for PrimePay, a private-equity-backed human capital management software company. His expertise spans the full spectrum of SaaS business models, recurring revenue optimization and the financial metrics critical to scaling AI-driven healthcare technologies. "Mike's proven track record of driving financial excellence and operational scale makes him the ideal leader to guide ConcertAI through our next phase of growth," said Eron Kelly, Chief Executive Officer of ConcertAI. "His deep understanding of SaaS models, combined with his experience in AI and technology sectors, aligns perfectly with our mission to accelerate breakthroughs in life sciences and healthcare through innovative AI solutions." Myshrall's appointment comes as ConcertAI continues to expand its comprehensive platform that unifies real-world data, AI innovation, and clinical expertise. The company's integrated solutions span from drug discovery to clinical trials to patient care delivery, serving major pharmaceutical companies and leading healthcare institutions worldwide. A Harvard Business School Master of Business Administration graduate and former management consultant, Myshrall has led mergers and acquisitions, capital raising efforts and complex financial transactions throughout his career. His experience includes successful public offerings, private equity investments and the implementation of advanced financial planning and analysis systems optimized for SaaS and AI business models. About ConcertAI ConcertAI is the leader in predictive and generative AI SaaS and real-world data research solutions for healthcare and life sciences. Our mission is to accelerate insights and outcomes for patients through research-ready data, CARAai™ technologies, and scientific expertise in partnership with over 46 leading biomedical innovators, 2,000 healthcare providers, and medical societies. TeraRecon provides advanced radiological image visualizations and clinical AI decision augmentation solutions for MRI and CT. CancerLinQ® is an initiative of ConcertAI, providing oncology providers with ASCO-aligned automated QOPI and ASCO Certified® quality solutions and SmartLinQ™ analytic services. Headquartered in Cambridge, Mass., ConcertAI has offices in Bangalore, Frankfurt, Philadelphia, Raleigh-Durham, and Tokyo. For more information, visit us at
Time Business News
2 hours ago
- Time Business News
Go Green Global Announces Merger Talks, Product Milestones, and First Commercial Sales in Transformative Quarter
NEW YORK, NY – Go Green Global Technologies Corp. (OTC: GOGR), a clean technology company, has unveiled a series of strategic moves, signaling a transformative period of growth and innovation. The company announced it has signed a non-binding Letter of Intent (LOI) to merge with an AI and robotics firm, achieved its first commercial sales for its CALCLEAR™ water-treatment line in North America, and reported significant progress in the field validation of its core Sonical™ technology platform. The cornerstone of the announcement is the planned merger with Four DRobotics® Corp. ('FDR'), a Canadian automation and robotics company that specializes in edge-controlled systems for mission-critical sectors such as mining, utilities, and defense. The LOI outlines the intent to merge the two companies into a single, vertically integrated entity. This new enterprise would combine Go Green's patented Sonical™ pulsed-power hardware with FDR's advanced autonomous robotics and edge-intelligent control software. The companies plan to launch a joint R&D division to explore deep integration possibilities, with the first pilot initiative being an autonomous AI HVAC optimization system. This system will fuse intelligent automation with Sonical™ flow-conditioning to deliver measurable improvements in energy usage and predictive maintenance. 'We're at a pivotal moment in the evolution of agentic AI, and this merger allows us to pioneer intelligent systems that combine software autonomy with high-impact hardware,' said Corrine Couch, Chief Operating Officer of Go Green Global Technologies. 'By aligning with Four DRobotics, we can accelerate our mission to deliver sustainability solutions that not only protect the planet but also drive real savings for our customers.' Jeremy James, President of Four DRobotics, echoed the sentiment. 'Integration of Go Green's Sonical™ platform with our Agentic AI solution creates a unified cyber-physical system capable of self-optimizing performance across energy, water, and industrial applications,' he stated. Beyond strategic partnerships, Go Green has secured its first commercial revenue in the North American market for its CALCLEAR™ product line. The company, which is the exclusive North American distributor for CALCLEAR™, sold 20 units to an HVAC company based in Norwalk, CT, for resale to retail and commercial customers. This entry is aimed at the global descaler market, which was valued at $9 billion in 2023 and is forecasted to expand at a compound annual growth rate (CAGR) of 9% through 2030, according to Verified Market Reports. CALCLEAR™ units are designed as a chemical-free solution to prevent mineral and scale build-up in boilers, cooling towers, and water heaters, a significant cause of energy inefficiency in the HVAC industry. 'We're seeing great interest in the product and look forward to expanding our network of sub-distributors,' commented Ms. Couch. Parallel progress is being made on the company's foundational Sonical™ platform, a patented technology that uses a low-voltage electro-physical device to create a pulsed variable electric field. This field alters fluids at a molecular level to improve efficiency and treat water without chemicals. Recent early-stage field trials of Sonical™ water treatment units in residential environments have yielded promising outcomes, showing a significant reduction in existing scale and preventing new deposits. Meanwhile, development continues on Sonical™ fuel treatment units, which are aimed at improving combustion and reducing emissions. Following a Memorandum of Understanding, partner company Camber Energy (OTCQB: CEIN) has received earlier-generation units and is preparing a comprehensive testing protocol to guide the design of next-generation prototypes. Together, these developments in M&A, commercial sales, and technology validation mark a period of accelerated activity for Go Green Global Technologies as it works to scale its impact across the water, fuel, and energy sectors Disclaimer: The content provided in this article is for informational purposes only and does not constitute financial, investment, or trading advice, nor is it a recommendation or solicitation to buy or sell any security. All investing involves significant risk, including the possible complete loss of principal. Readers should conduct their own due diligence and consult a qualified, licensed financial professional before making any investment decisions. The authors and publishers of this site are not liable for any financial losses or damages incurred based on the information provided herein. TIME BUSINESS NEWS
